Paper Details

  1. Home
  2. Paper Details

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Author: AbdallaS, BlockG A, ChangT I, ChertowG M, Correa-RotterR, DehmelB, DrüekeT B, FloegeJ, GoodmanW G, HerzogC A, LondonG M, MahaffeyK W, MoeS M, ParfreyP S, WheelerD C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Cinacalcet treatment in patients with secondary hyperparathyroidism (sHPT) and end-stage renal disease was associated with a lower risk of death and major cardiovascular events and a significant decrease in blood pressure.
Paper Details　
Original Abstract of the Article :
Patients with end-stage renal disease often have derangements in calcium and phosphorus homeostasis and resultant secondary hyperparathyroidism (sHPT), which may contribute to the high prevalence of arterial stiffness and hypertension. We conducted a secondary analysis of the Evaluation of Cinacalce...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/jhh.2015.56

データ提供：米国国立医学図書館（NLM）

Cinacalcet: A Potential Benefit for Cardiovascular Health in End-Stage Renal Disease

The world of nephrology is a complex desert, where numerous challenges affect individuals with kidney disease. End-stage renal disease (ESRD) often leads to derangements in mineral metabolism, including secondary hyperparathyroidism (sHPT), which can contribute to cardiovascular complications. This research explores the potential benefits of cinacalcet, a medication used to manage sHPT, on cardiovascular outcomes in patients with ESRD.

Cinacalcet and Cardiovascular Health in ESRD

This study, a secondary analysis of the EVOLVE trial, investigated the effect of cinacalcet on death and major cardiovascular events in patients with ESRD and sHPT. The study found that cinacalcet resulted in a nominally significant lower risk of the primary composite end point (all-cause mortality or non-fatal cardiovascular events) after adjusting for baseline characteristics. Additionally, cinacalcet resulted in a larger average decrease in systolic and diastolic blood pressure compared to placebo.

Potential Implications for Cardiovascular Care

The findings of this study suggest that cinacalcet may offer potential benefits for cardiovascular health in patients with ESRD and sHPT. While further research is needed to confirm these findings, the study suggests that cinacalcet's ability to manage sHPT may also contribute to improved cardiovascular outcomes. This research highlights the importance of considering the multifaceted effects of medications in managing complex chronic conditions.

Dr. Camel's Conclusion

This study provides insights into the potential cardiovascular benefits of cinacalcet in patients with end-stage renal disease and secondary hyperparathyroidism. While the findings require further investigation, the study suggests that cinacalcet may offer a potential avenue for improving cardiovascular health in this vulnerable population. This research highlights the importance of exploring the broader effects of medications and considering their potential impact on multiple organ systems, particularly in individuals with complex chronic conditions.

Date :
  1. Date Completed 2016-12-13
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26040438

DOI: Digital Object Identifier

10.1038/jhh.2015.56

Related Literature

Article Analysis
・Effects of cinacalcet
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.